1-3 of 3
Lance Leopold, MD
Close
Sort by
Journal Articles

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD, PhD, Martin Griesshammer, Prof. Dr. med., Tamás Masszi, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Pierre Zachee, MD, PhD, Fabrizio Pane, MD, Claire N Harrison, DM, FRCP, FRCPath, Shui He, PhD, Lance Leopold, MD, Jingjin Li, Ulrich Pirron, PhD, Tomasz Lawniczek, MD, PhD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4071.
https://doi.org/10.1182/blood.V122.21.4071.4071
Published: 2013
Journal Articles

An Open-Label, Phase II Study Of The JAK1 Inhibitor INCB039110 In Patients With Myelofibrosis

John Mascarenhas, MD, Moshe Talpaz, MD, Vikas Gupta, MD, FRCP, FRCPath, Michael Savona, MD, FACP, Paul Coughlin, FRACP, PhD, Elliott Winton, MD, Deborah Hunter, PhD, Bijoyesh Mookerjee, MD, FACP, Lance Leopold, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 663.
https://doi.org/10.1182/blood.V122.21.663.663
Published: 2013
Journal Articles

Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 10 9 /L): A Comparison to Patients with Normal or High Starting Platelet Counts

Moshe Talpaz, MD, Ronald Paquette, MD, PhD, Lawrence Afrin, MD, Solomon Hamburg, MD, PhD, Katarzyna Jamieson, MD, Howard Terebelo, DO, Gregory Ortega, MD, Roger M. Lyons, MD, Ramon V. Tiu, MD, BS, Elliott F. Winton, MD, Kavita Natrajan, MD, Olatoyosi Odenike, MD, Wei Peng, PhD, Victor A. Sandor, MD, CM, Peter O'Neill, MBA, CCRP, Sue Erickson-Viitanen, PhD, Lance Leopold, MD, Richard S Levy, MD, Hagop M Kantarjian, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 176.
https://doi.org/10.1182/blood.V120.21.176.176
Published: 2012